Cited by 562Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and MutationsMelanoma and MAPK Pathways

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Open access

Lee, Ho-June, Zhuang, Guanglei, Cao, Yi, Du, Pan, Kim, Hyo-Jin, Settleman, Jeff·2014·Cancer Cell

DOI 10.1016/j.ccr.2014.05.019

Open this paper in CoChat — free account Open PDF

Abstract

Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells. We found that many drug-treated "oncogene-addicted" cancer cells engage a positive feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response. This was observed in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS. Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacological inhibition of MEK together with JAK and FGFR enhanced tumor regression. These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.05.019

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,363
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Self-citation
Stat3 as an Oncogene
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Self-citation

Flagged first, then by citations

Show all 40 references

1 of the 40 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 562

Xiaoji decoction induces apoptosis in lung cancer cells and M1 Macrophage polarization via the JAK1/STAT3/PD-L1 pathway
He, C., Lu, Y., Wang, T., Zhang, B., Su, Z., Tang, L., Tao, L.-T., Zheng, G., Li, L., Feng, B., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120240 · Cited by 8
Ferroptosis: The dawn of reversing drug resistance in digestive cancers
Chen, W., Han, L., Wang, J., & Song, L. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101873 · Cited by 8
Targeting STAT3-mediated autophagy with small molecules in cancer treatment – A comprehensive review
Azad, S. M. A. K., Meem, J. N., Shaikat, A. H., Ali, M. L., Arif, M. S. R., Sabrin, S., Mostaq, M. S., Haque, M. R. U., Amin, M. N., & Mahmud, M. A. (2024) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2024.200174 · Cited by 8
Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
Xu, W., Bi, Y., Zhang, J., Kong, J., Jiang, H., Tian, M., Li, K., Wang, B., Chen, C., Song, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6111 · Cited by 8
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
Murone, M., Chessex, A. V., Attinger, A., Ramachandra, R. K., Shetty, S. J., Daginakatte, G., Sengupta, S., Marappan, S., Dhodheri, S., Rigotti, S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0974 · Cited by 8
TNFa inhibitor C87 sensitizes EGFRvIII transfected glioblastoma cells to gefitinib by a concurrent blockade of TNFa signaling
Ma, L., She, C., Shi, Q., Yin, Q., Ji, X., Wang, Y., Fan, Y., Kong, X., Li, P., Sun, Z., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0011 · Cited by 8
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer
Naeini, M. M., Tavassoli, M., & Ghaedi, K. (2018) · Gene · doi:10.1016/j.gene.2018.04.077 · Cited by 8
Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Chai, C.-S., Liam, C. K., Poh, M. E., Ong, D. B., Pang, Y., Cheah, P., Ho, G. F., & Alip, A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s253760 · Cited by 8
Anaplastic lymphoma kinase (alk), a neuroblastoma associated gene, is expressed in neural crest domains during embryonic development of Xenopus
Moreno, M. M., Barrell, W. B., Godwin, A., Guille, M., & Liu, K. J. (2021) · Gene Expression Patterns · doi:10.1016/j.gep.2021.119183 · Cited by 8
The power of the fewPreprint
Chen, R., Pan, Y., & Gutmann, D. H. (2017) · Genes & Development · doi:10.1101/gad.303453.117 · Cited by 8
Advances of signal transducer and activator of transcription 3 inhibitors in acute myeloid leukemia (Review)
Cheng, H., Chen, L., & Huang, C. (2025) · Oncology Letters · doi:10.3892/ol.2025.14881 · Cited by 7
RePhine: An Integrative Method for Identification of Drug Response-Related Transcriptional Regulators
Wang, X., Zhang, Z., Qin, W., Liu, S., Liu, C., Genchev, G. Z., Hui, L., Zhao, H., & Lu, H. J. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.09.008 · Cited by 7
Multidrug Resistance Reversed by Maleimide Interactions. A Biological and Synthetic Overview for an Emerging Field
Hernández‐Velázquez, E. D., Granados‐López, A. J., López, J. A., & Solorio‐Alvarado, C. R. (2024) · ChemBioChem · doi:10.1002/cbic.202400640 · Cited by 7
Unravelling key signaling pathways for the therapeutic targeting of non-small cell lung cancer
Chavan, P. R., Pandey, R., Patil, B. M., Murti, K., & Kumar, N. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177494 · Cited by 7
The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance
Dawalibi, A., Bakir, M. A., & Mohammad, K. S. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.28 · Cited by 8
Apoptosis and cell cycle arrest of hepatocellular carcinoma spheroids treated by an alternating electric field
Huang, C., Lei, K. F., & Tsang, N. (2019) · Biotechnology Progress · doi:10.1002/btpr.2787 · Cited by 7
Niraparib-induced STAT3 inhibition increases its antitumor effects
Zhao, Q., Kohut, A. Y., Li, Y., Martincuks, A., Austria, T., Zhang, C., Santiago, N. L., Borrero, R. M., Phan, X. T., Melstrom, L. G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.966492 · Cited by 7
Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors
Wu, D., Lei, Y., Liu, Q., Hu, H., Li, H., Xie, L., & Zhou, J. (2021) · Medicine · doi:10.1097/md.0000000000023777 · Cited by 7
MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells
Makabe, S., Hoshi, K., Kaneko, H., Masuishi, Y., Yaginuma, K., Meguro, S., Onagi, A., Hoshi, S., Hata, J., Ito, H., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08221-8 · Cited by 6
Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
Žák, J., & Teijaro, J. R. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01266-6 · Cited by 6
Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
Wu, C., Liu, X., Liu, R., Song, S., Zheng, Z., Zeng, Y., Mei, Y., Zhang, J., Duan, Q.-J., Lin, R., et al. (2024) · Advanced Science · doi:10.1002/advs.202407239 · Cited by 7
The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer
Li, J., Shan, K., Huang, W., Su, Q., Qi, Y., Zhang, Z., Zhu, J., & Du, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432586 · Cited by 6
Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy
Gaillard, B., Seguin, C., Rémy, J.-S., Pons, F., & Lebeau, L. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201903976 · Cited by 6
Identification of serum and glucocorticoid-regulated kinase 1 as a regulator of signal transducer and activator of transcription 3 signaling
Araki, T., Watanabe, Y., Okada, Y., Murakami, H., Ogo, N., & Asai, A. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113079 · Cited by 6
A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway
Zhang, B., Li, B., Xie, Y., Chang, S., Xu, Z., Hu, H., Chen, G., Zhang, T., He, J., Wu, X., et al. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023014 · Cited by 6
Lung cancer treatment potential and limits associated with the STAT family of transcription factors
Faida, P., Attiogbe, M. K. I., Majeed, U., Zhao, J., Qu, L., & Fan, D. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110797 · Cited by 6
A Biodegradable Nucleotide Coordination Polymer for Enhanced NSCLC Therapy in Combination with Metabolic Modulation
Zhang, J., Li, X., Yin, Y., Cao, G., & Wang, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302187 · Cited by 6
Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies the Emergence of Drug-Tolerant Cancer Cells
Celeste, F., & Powers, S. (2024) · Cancers · doi:10.3390/cancers16051001 · Cited by 6
Quantitative Monitoring of the Response of Tumor Spheroids Cultured in 3D Environment by Optical Coherence Tomography
Tsai, M., Huang, B.-H., & Lei, K. F. (2020) · IEEE Access · doi:10.1109/access.2020.2972620 · Cited by 8
Twenty five years of Cytokine: on a forward path to exciting discoveries of pathological mechanisms and therapeutics
Kalvakolanu, D. V. (2017) · Cytokine · doi:10.1016/j.cyto.2017.08.008 · Cited by 6
EGFR blockade activates interferon
Yoshida, R., & Barbie, D. A. (2020) · Nature Cancer · doi:10.1038/s43018-020-0055-1 · Cited by 6
Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities
Chan, W. Y., da Silva, I. P., Long, G. V., & Rizos, H. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00199-6 · Cited by 5
pSTAT3 transactivates EGFR in maintaining EGFR protein homeostasis and EGFR-TKI resistance
Ao, J., Fei, J., Wang, G., Zhang, W., Yu, S., Guo, R., Niu, M., Chen, H., Cao, Y., Xiao, Z. J., et al. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024166 · Cited by 5
Self-citation
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)
Aroldi, F., Élez, E., André, T., Perkins, G., Prenen, H., Popovici, V. C., Gallagher, P. F., Houlden, J., Collins, L., Roberts, C., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14068-1 · Cited by 5
Stratifin Is Necessary for Spasmolytic Polypeptide-Expressing Metaplasia Development After Acute Gastric Injury
Won, Y., Sohn, Y., Lee, S., Goldstein, A. E., Gangula, R., Mallal, S. A., & Goldenring, J. R. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101521 · Cited by 5
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Brunet, L. J., Alexandre, D., Lee, J., Blanquer-Rosselló, M. D. M., Bracquemond, D., Guernet, A. A., Chhouri, H., Goupil, M., Kherrouche, Z., Arabo, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61788-w · Cited by 5
KDF1 Promoted Proliferation, Migration and Invasion of Lung Adenocarcinoma Cells through Activating STAT3 and AKT Pathway
Guo, Y., Gan, M., Bao, J., Zhou, H.-X., Yang, J., Dai, C., & Zheng, J. (2023) · Biomedicines · doi:10.3390/biomedicines11123194 · Cited by 5
Cloning of the promoter region of a human gene, FOXL2, and its regulation by STAT3
Han, Y., Wang, T., Sun, S., Zhai, Z., & Tang, S. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6914 · Cited by 5
Patulin and LL‐Z1640 ‐2 induce apoptosis of cancer cells by decreasing endogenous protein levels of Zic family member 5
Satow, R., Watanabe, T., Nomura, M., Inagaki, S., Yoneda, A., & Fukami, K. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17598 · Cited by 5
Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer
Zhao, X., Xu, Z., Meng, B., Ren, T., Wang, X., Hou, R., Li, S., Ma, W., Liu, D., Zheng, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47961-5 · Cited by 5
Targeting Minimal Residual Disease
Chou, Y., Allegakoen, P., & Bivona, T. G. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070924-120742 · Cited by 4
The STAT3–ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer
Chang, T., Tsai, M., Wu, S.-G., Liu, Y., Wu, H., Tsai, T.-H., Jheng, H.-N., Hsu, C., Yeh, P.-S., & Shih, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1699471 · Cited by 4
The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance
Shirbhate, E., Singh, V. P., Kore, R., Vishwakarma, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266284527240118041129 · Cited by 4
Harnessing transcriptomics for discovery of natural products to overcome acquired cancer resistance
Yeo, H., Kim, S.-Y., & Park, S. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01590-w · Cited by 4
Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway
Li, C., Shi, S., Li, L., Wang, Y., Yao, M., Yu, C., Yu, C., & Xie, C. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08220-9 · Cited by 4
Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment
Lee, D. H., Yoo, J. K., Um, K. H., Ha, W., Lee, S. M., Park, J., Kye, M. J., Suh, J., & Choi, J. W. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03088-7 · Cited by 4
Crosstalk between circular RNAs and the STAT3 signaling pathway in human cancer
Almouh, M., Soukkarieh, C., Kassouha, M., & Ibrahim, S. (2024) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2024.195051 · Cited by 4
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Lazzari, C., Verlicchi, A., Γκουντάκος, Α., Pilotto, S., Santarpía, M., CHAIB-OUKADOUR, I., Ramírez, J. L., Viteri, S., Morales-Espinosa, D., Dazzi, C., et al. (2016) · Pulmonary Therapy · doi:10.1007/s41030-016-0013-3 · Cited by 4
Matrix‐assisted laser desorption ionization ‐ mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a non‐small‐cell lung cancer mouse xenograft model
Kim, T. Y., Lee, B., Kim, Y., Sugihara, Y., Rezeli, M., Szasz, A. M., Döme, B., Marko‐Varga, G., & Kwon, H. J. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.481 · Cited by 4
Feed‐forward activation of STAT3 signaling limits the efficacy of c‐Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment
Zhao, D., Chen, J., Wang, Y., Zhang, L., Zhang, J., Zhang, W., Fan, J., Li, J., & Zhan, Q. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23306 · Cited by 4
Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients
Petrusel, L., Ilies, M., Leucuta, D., Rusu, I., Seicean, A., Iuga, C. A., & Seicean, R. (2021) · Cellular and Molecular Biology · doi:10.14715/cmb/2021.67.3.14 · Cited by 4
Predicting the prognosis of esophageal cancer based on extensive analysis of new inflammatory response‐related signature
He, H., Zhang, P., Li, F., Zeng, C., Liu, D., & Wu, K. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23291 · Cited by 4
Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform
Casas, C. M. D. L., Garzón‐Ibáñez, M., Jordana‐Ariza, N., Viteri, S., Moya‐Horno, I., Karachaliou, N., Yeste, Z., Campos, R., Villatoro, S., Balada‐Bel, A., et al. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.12 · Cited by 4
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Pan, Z., Qian, Y., Wang, Y., Zhang, T.-S., Song, X., Ding, H., Li, R., Zhang, Y., Wang, Z., Wang, H., et al. (2025) · Cancer Science · doi:10.1111/cas.70017 · Cited by 3
Effects ofSTAT3polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR‐mutation positive non‐small cell lung cancer
Yokota, H., Sato, K., Sakamoto, S., Okuda, Y., Asano, M., Takeda, M., Nakayama, K., & Miura, M. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13173 · Cited by 3
Inhibition of JAK/STAT3 Expression by Acute Myeloid Leukemia-Targeted Nanoliposome for Chemotherapy Enhancement
Zuo, Y., Li, H., Wang, X., Liang, Y., Huang, C., Nai, G., Ruan, J., Dong, W., & Lu, X. (2024) · ACS Omega · doi:10.1021/acsomega.4c00710 · Cited by 3
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers
Gallagher, P. F., Rolfo, C. D., Élez, E., Taı̈eb, J., Houlden, J., Collins, L., Roberts, C., André, T., Lawler, M., Nicolantonio, F. D., et al. (2025) · BJC Reports · doi:10.1038/s44276-025-00133-6 · Cited by 3
Existence, stability, and numerical simulation of a nonlinear brain tumor model
Afshari, H., Kalantari, S., Anvari, M., & Marasi, H. R. (2025) · Journal of Inequalities and Applications · doi:10.1186/s13660-025-03276-9 · Cited by 3
Comprehensive analysis of a new immune-related prognostic signature for esophageal cancer and its correlation with infiltrating immune cells and target genes
Zhang, P., Liu, X., Cheng, Z., Wu, K., & Zhao, S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4756 · Cited by 3
Modeling CAF-tumor interactions to overcome therapy resistance
Gubała, J., Benamran, D. A., Tsantoulis, P. K., Mieville, V., Valério, M., & Nowak-Sliwinska, P. M. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03633-y · Cited by 2
Dual Gene Delivery Reagents From Antiproliferative Alkylphospholipids for Combined Antitumor Therapy
Gaillard, B., Rémy, J.-S., Pons, F., & Lebeau, L. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.581260 · Cited by 2
Analysis of a Cancer Stem Cell-Derived Single Colony Raised in a Microwell Array
Lei, K. F., Chen, Q.-E., Goh, A., & Pai, P. C. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00209 · Cited by 2
Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer
Park, S., Haam, K., Heo, H., Kim, D., Kim, M., Jung, H., Cha, S., Kim, S., & Lee, H. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13738 · Cited by 2
Self-citation
Development of Adamantane-based hydrophobic tags targeting anaplastic lymphoma kinase with enhanced antitumor activities
Zhu, J., Zhan, F., Xie, J., Fang, T., Sun, Y., Zhan, F., Gao, T. X., Liu, J. Y., Feng, J., Zhou, P., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108876 · Cited by 2
Phospho-EGFRTyr992 is synergistically repressed by co-inhibition of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K), which attenuates resistance to erlotinib in head and neck cancer cells
Chen, X., Gao, W., Yin, G., Guo, W., Huang, J., Huang, Z., & Zhang, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4335 · Cited by 2
Systemic Inflammatory Response as a Prognostic Factor in Breast Cancer. Part I. Tumor-Promoting Inflammation. Serum Inflammatory Markers
Sergeeva, N. S., Анатольевна, К. Т., Polyak, M. A., Игоревич, А. И., & Каприн, А. Д. (2022) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn2229 · Cited by 2
Fedratinib and gandotinib induce apoptosis and enhance the efficacy of tyrosine kinase inhibitors in human mast cells
Makeeva, A. (2025) · American Journal of Cancer Research · doi:10.62347/tytu4465 · Cited by 2
Effects of Induced Pluripotent Stem Cell-Derived Astrocytes on Cisplatin Sensitivity in Pediatric Brain Cancer Cells
Kiran, S., Xue, Y., Sarker, D. B., & Sang, Q. A. (2025) · Cancers · doi:10.3390/cancers17060997 · Cited by 2
STAT3 sustains tumorigenicity following mutant KRAS ablation
D’Amico, S., Kirillov, V., Liu, J., Qiu, Z., Lei, X., Qin, H., Sheridan, B. S., & Reich, N. C. (2025) · EMBO Reports · doi:10.1038/s44319-025-00563-w · Cited by 2
Targeting Signal Transducer and Activator of Transcription 3 for Colorectal Cancer Prevention and Treatment with Natural Products
Hua, B., Li, W., Chen, C., & Liu, Z. (2016) · Cancer translational medicine · doi:10.4103/2395-3977.181435 · Cited by 2
Characterizing the last holdouts
Stewart, E., & Tsao, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15090 · Cited by 2
Cytotoxicity of carnosine, taxifolin, linalool and their combinations with acids to the cells of human cervical carcinoma (HeLa)
Rokaitytė, A., Zaborskienė, G., Baliukonienė, V., Jovaišienė, J., & Gustienė, S. (2019) · Biologija · doi:10.6001/biologija.v64i4.3900 · Cited by 2
Evaluation of the combined effect of naringin and imatinib in philadelphia positive chronic myeloid leukemia
Gudimetla, K., & Orsu, P. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.7888 · Cited by 2
p27 specifically decreases in squamous carcinoma, and mediates NNK ‐induced transformation of human bronchial epithelial cells
Peng, M., Meng, H., Wang, J., Guo, M., Li, T., Qian, X., Chen, R., Jin, H., & Huang, C. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18577 · Cited by 2
STAT Proteins in Cancer
O’Keefe, R. A., & Grandis, J. R. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_2 · Cited by 2
Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?
Suda, K. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.05.21 · Cited by 2
MEK Inhibitors in Lung Cancer—You Can Teach an Old Drug New Tricks
Havel, J. J. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2590 · Cited by 2
Untersuchungen zur Chemotherapieresistenz von H8N8-Tumorzellen nach Cyclophosphamid-, Doxorubicin- und 5-Fluouraciltherapie im syngenen WAP-T-Mammakarzinom-Mausmodell
Reinhardt, O. (2019) · doi:10.53846/goediss-7646 · Cited by 2
Oncogenic pathways as the basis of primary immune ignorance
Patel, M. R. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170081 · Cited by 1
Bazedoxifene Inhibits Cell Viability, Colony‐Forming Activity, and Cell Migration in Human Non – Small Cell Lung Cancer Cells and Improves the Treatment Efficacy of Paclitaxel and Gemcitabine
Huang, Y., Lin, J., Fu, X., Li, L., & Fu, S. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13822 · Cited by 1
Stress-responsive membrane proteins as execution nodes of tumor cell adaptation to microenvironmental stress
He, X., Huang, T., WANG, Z., Bu, F., Cao, X., Xu, M., & Wu, C. (2026) · Oncogene · doi:10.1038/s41388-026-03768-y · Cited by 2
Mitochondrial Metabolic Reprogramming in Colorectal Cancer-Associated Fibroblasts: An Up-to-Date Review
Li, Y., Chanda, D., Jeon, S.-W., Jeon, J., & Kim, M.-J. (2026) · Cancers · doi:10.3390/cancers18111786 · Cited by 1
Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers after complete resection: a retrospective real-world study
Yang, X. C., Song, Y., Xu, R., Yang, Y., Feng, L., Qi, Q., Li, H., Yu, Z., Wang, J., & An, N. (2025) · BMC Cancer · doi:10.1186/s12885-025-13667-2 · Cited by 1
Buddlejasaponin IV inhibits proliferation and migration via STAT3 suppression in gefitinib-resistant non-small cell lung cancer cells
Jang, S. C., Kim, D., Han, J., Moon, D. H., Bae, E. S., Ock, C. W., Park, H. J., & Lee, S. K. (2026) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-026-05294-6 · Cited by 1
The JAK/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications
Liao, Y., Wei, Q., Song, H., Zeng, H., Qi, C., Meng, Y., Zhang, Y., Zhang, Y., Li, W., Li, Y., et al. (2026) · MedComm – Oncology · doi:10.1002/mog2.70063 · Cited by 1
Prospects of circular RNAs: the regulators of drug resistance and metastasis in gastric cancer.
Wang, B., Chen, Z., Liu, W., & Tan, B. (2022) · PubMed Central · Cited by 1
MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer
Kim, S., Lee, K. W., Yoo, Y., Park, S. H., Lee, J. W., Jeon, S., Illia, S., Joshi, P., Park, H. W., Lo, H. ‐., et al. (2024) · Animal Cells and Systems · doi:10.1080/19768354.2024.2345644 · Cited by 1
STAT3 as a Major Contributor to Chemoresistance
Lee, D. S., Grandis, J. R., & Johnson, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00007-x · Cited by 1
Resistance to EGFR Targeting Treatments in Colorectal Cancer
Pucci, M., & Lauriola, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00018-1 · Cited by 1
Kinase Inhibitors
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00003-2 · Cited by 1
Ruxolitinib
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00017-2 · Cited by 1
Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
Rosell, R., Karachaliou, N., Codony, C., & Ito, M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.20 · Cited by 1
Molecular Mechanism of Multi‐Drug Resistant Cancer Cells
Malviya, R., Singh, A. K., & Yadav, D. (2023) · Wiley eBooks · doi:10.1002/9781394209866.ch3 · Cited by 1
A conversation with Jeffrey Settleman
Lou, K.-J. (2014) · Science-Business eXchange · doi:10.1038/scibx.2014.1113
Targeting Cancer Stem Cells and the Tumor Microenvironment
Turdo, A., Todaro, M., & Stassi, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_16 · Cited by 1
The role of fibroblast PPAR??/?? in skin homeostasis
Sng, M. K. (2016) · doi:10.32657/10356/66431
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells Supplementary Issue: Signaling Pathways as Biomarkers
Groysman, J., & Pongtornpipat, P. (2015)
STATs in Health and Disease
Liongue, C., Lewis, R. S., & Ward, A. C. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_1
A sensible approach to targeting STAT3-mediated transcription
Bhola, N. E., Johnson, D. E., & Grandis, J. R. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.10.51
Mechanisms of IKBKE Activation in Cancer
Challa, S. (2017) · Digital Commons - University of South Florida (University of South Florida)

Authors: Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J.
Affiliations: Genentech (US)
Corresponding author: Settleman, Jeff
ORCID: Lee, Ho-June
Zhuang, Guanglei
Cao, Yi
Du, Pan
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2014-08
Volume: 26
Issue: 2
Pages: 207-221
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2014.05.019
OpenAlex: W2102365935
Cited by: 555
References: 40
Citations by year: 2026: 23 · 2025: 27 · 2024: 36 · 2023: 41 · 2022: 38 · 2021: 61 · 2020: 55 · 2019: 63 · 2018: 46 · 2017: 65 · 2016: 54 · 2015: 42 · 2014: 4
FWCI: 26.52
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: STAT3, drug resistance, oncogene addiction, positive feedback loop, MEK inhibition, JAK inhibition, fibroblast growth factor receptor, EGFR, HER2, anaplastic lymphoma kinase, MET, mutant KRAS, autocrine signaling, combination therapy, tumor regression
MeSH terms: Erlotinib Hydrochloride, Adenocarcinoma of Lung, Adenocarcinoma, Animals, Antineoplastic Agents, Cell Survival, Humans, Imidazoles, Lung Neoplasms, Mutation, Nitriles, Oncogenes, Proto-Oncogene Proteins, Pyrazoles, Pyridazines, Pyrimidines, Quinazolines, Signal Transduction, Interleukin-6, Proto-Oncogene Proteins p21(ras), Mice, SCID, Receptors, Fibroblast Growth Factor, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, STAT3 Transcription Factor, Mice, Kaplan-Meier Estimate, Janus Kinase 1, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks